Skip to main content

Table 2 Higher CD38 is associated with a lower risk of recurrence after prostatectomy for clinically localized disease

From: CD38 is methylated in prostate cancer and regulates extracellular NAD+

Characteristic Model 1 p value Model 2 p value Model 3 p value
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Age at surgery (years) 0.81 (0.70–0.93) 0.003 0.81 (0.71–0.93) 0.003 0.81 (0.71–0.93) 0.003
Caucasian (yes/no) 0.09 (0.02–0.41) 0.002 0.10 (0.02–0.45) 0.003 0.11 (0.02–0.49) 0.004
High Gleason sum (yes/no) 1.44 (0.08–27.4) 0.819 1.80 (0.10–34.1) 0.715 1.41 (0.07–26.7) 0.831
S stage (yes/no) 2.09 (0.26–16.59) 0.487 2.06 (0.25–17.00) 0.502 2.31 (0.25–21.07) 0.457
Pre-op PSA (1 unit) 1.01 (0.99–1.03) 0.227 1.01 (0.99–1.03) 0.282 1.01 (0.99–1.03) 0.274
Surgical margins (+/−) 2.33 (1.65–3.30) < 0.001 2.25 (1.60–3.17) < 0.001 2.37 (1.68–3.36) < 0.001
CD38 above med. cancer 0.69 (0.52–0.91) 0.007 XX XX XX XX
CD38 above med. benign XX XX 0.91 (0.69–1.20) 0.505 XX XX
CD38 above med. for both XX XX XX XX 0.65 (0.48–0.88) 0.006
  1. Three conditional logistic regression models were run, each with the covariates mentioned above and CD38 as above the median in cancer cores (model 1), above the median in benign cores (model 2), and above the median in both (model 3). Odds ratios and 95% confidence intervals were extracted from each model